EYET Eyetech Pharmaceuticals (MM)

Eyetech to Present at the 2005 UBS Global Pharmaceuticals Conference NEW YORK, May 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) today announced that it will present at the 2005 UBS Global Pharmaceuticals Conference in New York City on May 24, 2005 at 8:30 a.m. Eastern Time. (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO ) Interested parties may access a live audio webcast of the presentation by logging on to the Investor Relations section of our corporate website at http://www.eyetech.com/. An archived version of the webcast will be available at the same location through May 31, 2005. About Eyetech Pharmaceuticals, Inc. Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen(R) (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD. Macugen is also being studied for other indications including diabetic macular edema and retinal vein occlusion. http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE: Eyetech Pharmaceuticals, Inc. CONTACT: Media: Chris Smith, Public Relations & Corporate Communications, Office: +1-212-824-3203, Mobile: +1-973-489-5076, , or Investors: Glenn Sblendorio, Chief Financial Officer, Office: +1-212-824-3121, , both of Eyetech Pharmaceuticals, Inc. Web site: http://www.eyetk.com/

Copyright